Gut microbial alteration in chronic spontaneous urticaria unresponsive to second generation antihistamines and its correlation with disease characteristics- a cross-sectional case-control study

IF 4.6 2区 医学 Q2 ALLERGY Clinical and Translational Allergy Pub Date : 2025-01-14 DOI:10.1002/clt2.70027
Indrashis Podder, David Pesqué, Nerea Carrón, Pedro Iñaki González Torres, Ramon M. Pujol, Ana M. Giménez-Arnau
{"title":"Gut microbial alteration in chronic spontaneous urticaria unresponsive to second generation antihistamines and its correlation with disease characteristics- a cross-sectional case-control study","authors":"Indrashis Podder,&nbsp;David Pesqué,&nbsp;Nerea Carrón,&nbsp;Pedro Iñaki González Torres,&nbsp;Ramon M. Pujol,&nbsp;Ana M. Giménez-Arnau","doi":"10.1002/clt2.70027","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Gut microbial involvement has been speculated in chronic spontaneous urticaria (CSU). The aim of the study was to compare the gut microbiome composition and diversity in CSU patients uncontrolled with second-generation antihistamines (sgAHs) and healthy individuals, as well as to explore any association between gut microbiome and disease characteristics.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A cross-sectional case-control study including 20 CSU patients unresponsive to standard doses of sgAHs, and 15 age-and-sex matched healthy controls was conducted. Clinico-demographic profile, laboratory investigations and stool analysis were conducted in all study participants. 16S RNA gene sequencing and DNA isolation was performed for all stool samples, followed by bioinformatic analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The CSU patients (mean age 39.5 ± 9.3, M:F 1:4) and healthy controls (mean age 35 ± 13, M:F 1:2) were statistically comparable. The median (IQR) duration of CSU was 42 months (7–81). Concomitant angioedema and concomitant symptomatic dermographism were present in 30% and 20% CSU patients, respectively. At inclusion, 60% patients were receiving add-on omalizumab, while the remaining 40% were on up-dosed sgAHs. Stool microbial analysis revealed increased diversity and higher microbial richness in CSU patients compared with healthy individuals. CSU patients showed reduced load of short-chain fatty acid (SCFA) producing microbiota and increased load of opportunistic pathogens. The Firmicutes/Bacteroides (F/B) ratio was higher in CSU patients. Among CSU patients, higher Bacteroides and reduced Firmicutes count were associated with higher disease activity and poor control; however, there was no link with the type of therapy.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Gut microbial dysbiosis is seen in CSU and is linked with disease control.</p>\n </section>\n </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 1","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11732700/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Allergy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clt2.70027","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Gut microbial involvement has been speculated in chronic spontaneous urticaria (CSU). The aim of the study was to compare the gut microbiome composition and diversity in CSU patients uncontrolled with second-generation antihistamines (sgAHs) and healthy individuals, as well as to explore any association between gut microbiome and disease characteristics.

Methods

A cross-sectional case-control study including 20 CSU patients unresponsive to standard doses of sgAHs, and 15 age-and-sex matched healthy controls was conducted. Clinico-demographic profile, laboratory investigations and stool analysis were conducted in all study participants. 16S RNA gene sequencing and DNA isolation was performed for all stool samples, followed by bioinformatic analysis.

Results

The CSU patients (mean age 39.5 ± 9.3, M:F 1:4) and healthy controls (mean age 35 ± 13, M:F 1:2) were statistically comparable. The median (IQR) duration of CSU was 42 months (7–81). Concomitant angioedema and concomitant symptomatic dermographism were present in 30% and 20% CSU patients, respectively. At inclusion, 60% patients were receiving add-on omalizumab, while the remaining 40% were on up-dosed sgAHs. Stool microbial analysis revealed increased diversity and higher microbial richness in CSU patients compared with healthy individuals. CSU patients showed reduced load of short-chain fatty acid (SCFA) producing microbiota and increased load of opportunistic pathogens. The Firmicutes/Bacteroides (F/B) ratio was higher in CSU patients. Among CSU patients, higher Bacteroides and reduced Firmicutes count were associated with higher disease activity and poor control; however, there was no link with the type of therapy.

Conclusion

Gut microbial dysbiosis is seen in CSU and is linked with disease control.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对第二代抗组胺药无反应的慢性自发性荨麻疹患者肠道微生物改变及其与疾病特征的相关性——一项横断面病例对照研究
背景:有人推测慢性自发性荨麻疹(CSU)与肠道微生物有关。本研究旨在比较使用第二代抗组胺药(sgAHs)未获控制的CSU患者和健康人的肠道微生物组组成和多样性,并探讨肠道微生物组与疾病特征之间的关联:一项横断面病例对照研究包括20名对标准剂量抗组胺药无反应的CSU患者和15名年龄与性别匹配的健康对照者。对所有研究对象进行了临床-人口学特征、实验室检查和粪便分析。对所有粪便样本进行了 16S RNA 基因测序和 DNA 分离,然后进行了生物信息学分析:CSU患者(平均年龄为39.5 ± 9.3,男女比例为1:4)和健康对照组(平均年龄为35 ± 13,男女比例为1:2)在统计学上具有可比性。CSU持续时间的中位数(IQR)为42个月(7-81)。分别有30%和20%的CSU患者伴有血管性水肿和症状性皮炎。纳入研究时,60%的患者正在接受奥马珠单抗的附加治疗,而其余40%的患者正在服用加量的sgAHs。粪便微生物分析显示,与健康人相比,CSU 患者的粪便微生物多样性增加,微生物丰富度提高。CSU患者体内产生短链脂肪酸(SCFA)的微生物群数量减少,机会性病原体数量增加。CSU 患者的固醇菌/乳酸菌(F/B)比率较高。在 CSU 患者中,较高的嗜酸乳杆菌(Bacteroides)和较低的固着菌(Firmicutes)数量与较高的疾病活动性和较差的控制率有关;但与治疗类型没有关联:结论:肠道微生物菌群失调可见于 CSU,并与疾病控制有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical and Translational Allergy
Clinical and Translational Allergy Immunology and Microbiology-Immunology
CiteScore
7.50
自引率
4.50%
发文量
117
审稿时长
12 weeks
期刊介绍: Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology, provides a platform for the dissemination of allergy research and reviews, as well as EAACI position papers, task force reports and guidelines, amongst an international scientific audience. Clinical and Translational Allergy accepts clinical and translational research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, or any other topic related to allergic disease.
期刊最新文献
Development of the symptomatic dermographism quality of life questionnaire Identifying integrins secreted in serum: Unveiling their correlation with inflammation and asthma—A preliminary study Issue Information Predictors of revision endoscopic sinus surgery in Finnish patients with chronic rhinosinusitis with nasal polyps T2-low severe asthma clinical spectrum and impact: The Greek PHOLLOW cross-sectional study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1